Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11272-11283

  Yokota, Tomoya ^a   Bui, Tuyen ^a   Liu, Yanna ^a   Yi, Min ^a   Hunt, Kelly K ^a   Keyomarsi, Khandan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; ELAFIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; BINDING SITE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CANCER TISSUE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE DELETION; GENE MAPPING; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BINDING SITES; BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL NUCLEUS; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; ELAFIN; ENHANCER ELEMENTS (GENETICS); FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; MIDDLE AGED; PROMOTER REGIONS (GENETICS); PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 37049011645     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2322     Document Type: Article

References (48)

1. Landschulz WH, Johnson PF, McKnight SL. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 1988;240:1759-64.
2. Grimm SL, Rosen JM. The role of C/EBPβ in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003;8:191-204.
3. Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem 1998;273:28545-8.
4. Zahnow CA, Cardiff RD, Laucirica R, Medina D, Rosen JM. A role for CCAAT/enhancer binding protein β-liver-enriched inhibitory protein in mammary epithelial cell proliferation. Cancer Res 2001;61:261-9.
5. Zahnow CA, Younes P, Laucirica R, Rosen JM. Overexpression of C/EBPβ-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. J Natl Cancer Inst 1997;89:1887-91.
6. Robinson GW, Johnson PF, Hennighausen L, Sterneck E. The C/EBPβ transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland. Genes Dev 1998;12:1907-16.
7. Seagroves TN, Krnacik S, Raught B, et al. C/EBPβ, but not C/EBPα, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. Genes Dev 1998;12:1917-28.
8. Sterneck E, Tessarollo L, Johnson PF. An essential role for C/EBPβ in female reproduction. Genes Dev 1997;11:2153-62.
9. Bundy LM, Sealy L. CCAAT/enhancer binding protein β (C/EBPβ)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture. Oncogene 2003;22:869-83.
10. Eaton EM, Hanlon M, Bundy L, Sealy L. Characterization of C/EBPβ isoforms in normal versus neoplastic mammary epithelial cells. J Cell Physiol 2001;189:91-105.
11. Jänicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinasetype plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001;93:913-20.
12. Look MP, van Putten WLJ, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activators and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28.
13. Urban P, Vuaroqueaux V, Labuhn M, et al. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. Clin Oncol 2006;24:4245-53.
14. Kao RT, Wong M, Stern R. Elastin degradation by proteases from cultured human breast cancer cells. Biochem Biophys Res Commun 1982;105:383-9.
15. Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer. Cancer Res 2003;63:337-41.
16. Foekens JA, Ries CH, Look MP, Gippner-Steppert C, Klijn JG, Jochum M. Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease. Br J Cancer 2003;88:1084-90.
17. Yamashita J, Akizuki M, Jotsuka T, Harao M, Nakano S. Neutrophil elastase predicts trastuzumab responsiveness in metastatic breast cancer. Breast J 2006;12:288.
18. Yamashita JI, Ogawa M, Shirakusa T. Free-form neutrophil elastase is an independent marker predicting recurrence in primary breast cancer. J Leukoc Biol 1995;57:375-8.
19. Yamashita JI, Ogawa M, Sato K. Prognostic significance of three novel biological factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 1995;117:601-8.
20. Schalkwijk J, de Roo C, de Jongh GJ. Skin-derived antileukoproteinase (SKALP), an elastase inhibitor from human keratinocytes. Purification and biochemical properties. Biochim Biophys Acta 1991;1096:148-54.
21. Schalkwijk J, Chang A, Janssen P, De Jongh GJ, Mier PD. Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis. Br J Dermatol 1990;122:631-41.
22. Zhang M, Zou Z, Maass N, Sager R. Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level. Cancer Res 1995;55:2537-41.
23. Liu Y, Chen JJ, Gao Q, et al. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol 1999;73:7297-307.
24. Gao Q, Singh L, Kumar A, Srinivasan S, Wazer DE, Band V. Human papillomavirus type 16 E6-induced degradation of E6TP1 correlates with its ability to immortalize human mammary epithelial cells. J Virol 2001;75:4459-66.
25. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996;56:4620-4.
26. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
27. Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50:6075-86.
28. Wolman SR, Mohamed AN, Heppner GH, Soule HD. Chromosomal markers of immortalization in human breast epithelium. Genes Chromosomes Cancer 1994;10:59-65.
29. Band V, De Caprio JA, Delmolino L, Kulesa V, Sager R. Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J Virol 1991;65:6671-6.
30. Band V, Zajchowski D, Kulesa V, Sager R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci U S A 1990;87:463-7.
31. Keyomarsi K, Conte D, Jr., Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene 1995;11:941-50.
32. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993;90:1112-6.
33. Pol A, Pfundt R, Zeeuwen P, Molhuizen H, Schalkwijk J. Transcriptional regulation of the elafin gene in human keratinocytes. J Invest Dermatol 2003;120:301-7.
34. 1 to multiple cell cycles by lovastatin. Cancer Res 1991;51:3602-9.
35. Harwell RM, Porter DC, Danes C. Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 2000;60:481-9.
36. Sambrook J, Russell DW. Chapter 17, Analysis of Gene Expression in Cultured Mammarian Cells. Molecular Cloning: A Laboratory Manual. 1st ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2001. p. 17.5-17.9.
37. Miller TL, McGee DW. Epithelial cells respond to proteolytic and non-proteolytic detachment by enhancing interleukin-6 responses. Immunology 2002;105:101-10.
38. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;105:1-78.
39. Matsusaka T, Fujikawa K, Nishio Y, et al. Transcription factors NF-IL6 and NF-κB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A 1993;105:10193-7.
40. Ki SH, Cho IJ, Choi DW, Kim SG. Glucocorticoid receptor (GR)-associated SMRT binding to C/EBPβ TAD and Nrf2 Neh4/5: role of SMRT recruited to GR in GSTA2 gene repression. Mol Cell Biol 2005;25:4150-65.
41. Rochford JJ, Semple RK, Laudes M, et al. ETO/MTG8 is an inhibitor of C/EBPh activity and a regulator of early adipogenesis. Mol Cell Biol 2004;24:9863-72.
42. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994;263:526-9.
43. Sheng S, Carey J, Seftor E, Dias L, Hendrix MJ. Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A 1996;93:11669-74.
44. Zhang M, Maass N, Magit D, Sager R. Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. Cell Growth Differ 1997;8:179-86.
45. Yamamoto S, Egami H, Kurizaki T, et al. Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of the oesophagus. Br J Cancer 1997;76:1081-6.
46. Robinson PA, Markham AF, Schalkwijk J, High AS. Increased elafin expression in cystic, dysplastic and neoplastic oral tissues. J Oral Pathol Med 1996;25:135-9.
47. Yoshida N, Egami H, Yamashita J, et al. Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of human lung. Oncol Rep 2002;9:495-501.
48. Alkemade HA, van Vlijmen-Willems IM, van Haelst UJ, van de Kerkhof PC, Schalkwijk J. Demonstra tion of skin-derived antileukoproteinase (SKALP) and its target enzyme human leukocyte elastase in squamous cell carcinoma. J Pathol 1994;174:121-9.